Advertisement

Tumor Suppressor Gene Therapy

  • Jack A. Roth
  • Susan F. Grammer
Part of the Methods in Molecular Biology™ book series (MIMB, volume 223)

Abstract

The preceding chapters in these two volumes on tumor suppressor genes (TSG) are a comprehensive compilation of what is currently known about the structure, function, activation, and regulation of TSGs, along with the roles they play in the myriad biochemical pathways that network to result in living cells. With recent developments in molecular genetics, new information is revealed daily, and it is likely that we have only scratched the surface of the base of knowledge about TSGs that will soon be available. Even so, the studies reported thus far have already led to the identification of genetic alterations in TSGs that are responsible, in whole or in part, for cancer, and subsequently to the development and implementation of formidable therapeutic strategies.

Keywords

Gene Therapy Gene Therapy Strategy Gene Therapy Protocol Gene Therapy Clinical Trial Cancer Therapy Evaluation Program 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Blaese, R. M., Culver, K. W., Miller, A. D., et al. (1995) T lymphocyte-directed gene therapy for ADA(−) SCID: initial trial results after 4 years. Science 270, 475–480.PubMedCrossRefGoogle Scholar
  2. 2.
    Crystal, R. G. (1995) Transfer of genes to humans: early lessons and obstacles to success. Science 270, 404–410.PubMedCrossRefGoogle Scholar
  3. 3.
    Kiem, H. P., von Kalle, D., Schuening, F., and Storb, R. (1995) Gene therapy and bone marrow transplantation. Curr. Opin. Oncol. 7, 107–114.PubMedCrossRefGoogle Scholar
  4. 4.
    Miller, N. and Vile, R. (1995) Targeted vectors for gene therapy. FASEB J. 9, 190–199.PubMedGoogle Scholar
  5. 5.
    Bishop, J. M. (1991) Molecular themes in oncogenesis. Cell 64, 235–248.PubMedCrossRefGoogle Scholar
  6. 6.
    Weinberg, R. A. (1991) Tumor suppressor genes. Science 254, 1138–1146.PubMedCrossRefGoogle Scholar
  7. 7.
    Cantley, L. and Neel, B. (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinas/AKT pathway. Proc. Natl. Acad. Sci. USA 96, 4240–4245.PubMedCrossRefGoogle Scholar
  8. 8.
    Burns, T. and El-Deiry, W. (1999) The p53 pathway and apoptosis. J. Cell. Physiol. 181, 231–239.PubMedCrossRefGoogle Scholar
  9. 9.
    NIH/RAC (2001). Report of the March 8, 2001, Meeting of the Recombinant DNA Advisory Committee. NIH/OBA/RAC website, 3-8-2001. 6-27-2001, http://www4.od.nih.gov/oba/rac/minutes/march32001.pdf.
  10. 10.
    Ramqvist, T., Magnusson, K. P., Wang, Y., Szekeley, L., and Klein, G. (1993) Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene 8, 1495–1500.PubMedGoogle Scholar
  11. 11.
    Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., and Costa, J. (1992) Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA 89, 4495–4499.PubMedCrossRefGoogle Scholar
  12. 12.
    Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. (1991) Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352, 345–347.PubMedCrossRefGoogle Scholar
  13. 13.
    Swisher, S. G., Roth, J. A., Komaki, R., et al. (2001) Induction of pro-apoptotic mediators and tumor regression following intratumoral delivery of adenoviral p53 (RPR/INGN 201) and radiation therapy in patients with non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20, 257a (abstr.).Google Scholar
  14. 14.
    Roth, J. A., Nguyen, D., Lawrence, D. D., et al. (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2, 985–991.PubMedCrossRefGoogle Scholar
  15. 15.
    Zhang, W. W., Fang, X., Mazur, W., French, B. A., Georges, R. N., and Roth, J. A. (1994) High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1, 5–13.PubMedGoogle Scholar
  16. 16.
    Swisher, S. G., Roth, J. A., Nemunaitis, J., et al. (1999) Adenovirus-mediated p53 gene transfer in advanced non-small cell lung cancer. J. Natl. Cancer Inst. 91, 763–771.PubMedCrossRefGoogle Scholar
  17. 17.
    Clayman, G. L., El-Naggar, A. K., Lippman, S. M., et al. (1998) Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. New Frontiers Res. Treat. Aerodigestive Tract Cancers 41, 109–110.Google Scholar
  18. 18.
    Goodwin, W. J., Esser, D., Clayman, G. L., Nemunaitis, J., Yver, A., and Dreiling, L. K. (1999) Randomized phase II study of intratumoral injection of two dosing schedules using a replication-deficient adenovirus carrying the p53 gene (AD5CMV-P53) in patients with recurrent/refractory head and neck cancer. Proc. Am. Soc. Clin. Oncol. 19, 445a (abstr.).Google Scholar
  19. 19.
    Bier-Laning, C. M., VanEcho, D., Yver, A., and Dreiling, L. K. (1999) A phase II multicenter study of AD5CMV-P53 administered intratumorally to patients with recurrent head and neck cancer. Proc. Am. Soc. Clin. Oncol. 18, 444a (abstr.).Google Scholar
  20. 20.
    Yver, A., Dreiling, L. K., Mohanty, S., et al. (1999) Tolerance and safety of RPR/INGN 201, an adeno-viral vector containing a p53 gene, administered intratumorally in 309 patients with advanced cancer enrolled in phase I and II studies world-wide. Proc. Am. Soc. Clin. Oncol. 19, 460a (abstr.).Google Scholar
  21. 21.
    Dewey, W. C., Ling, C. C., and Meyn, R. E. (1995) Radiation induced apoptosis: relevance to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 33, 781–796.PubMedCrossRefGoogle Scholar
  22. 22.
    Meyn, R. (1997) Apoptosis and response to radiation: implications for radiation therapy. Oncology 11, 349–366.PubMedGoogle Scholar
  23. 23.
    Meyn, R. E., Stephens, L.C., Hunter, N. R., and Milas, L. (1997) Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs 6, 443–450.CrossRefGoogle Scholar
  24. 24.
    Fujiwara, T., Cai, D. W., Georges, R. N., Mukhopadhyay, T., Grimm, E. A., and Roth, J. A. (1994) Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model (Commentary). J. Natl. Cancer Inst. 86, 1437–1438.CrossRefGoogle Scholar
  25. 25.
    Nguyen, D., Wiehle, S., Koch, P., Roth, J. A., and Cristiano, R. (1996) Gene therapy for lung cancer: enhancement of tumor suppression by a combination of systemic cisplatin and adenovirus-mediated p53 gene transfer. Proc. Am. Assoc. Cancer Res. 37, 347.Google Scholar
  26. 26.
    Hamada, M., Fujiwara, T., Hizuta, A., et al. (1996) The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J. Cancer Res. Clin. Oncol. 122, 360–365.PubMedCrossRefGoogle Scholar
  27. 27.
    Nemunaitis, J., Swisher, S. G., Timmons, T., et al. (2000) Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. J. Clin. Oncol. 18, 609–622.PubMedGoogle Scholar
  28. 28.
    Spitz, F. R., Nguyen, D., Skibber, J., Meyn, R., Cristiano, R. J., and Roth, J. A. (1996) Adenoviral mediated p53 gene therapy enhances radiation sensitivity of colorectal cancer cell lines. Proc. Am. Assoc. Cancer Res. 37, 347.Google Scholar
  29. 29.
    Jasty, R., Lu, J., Irwin, T., Suchard, S., Clarke, M. F., and Castle, V. P. (1998) Role of p53 in the regulation of irradiation-induced apoptosis in neuroblastoma cells. Mol. Genet. Metab. 65, 155–164.PubMedCrossRefGoogle Scholar
  30. 30.
    Feinmesser, M., Halpern, M., Fenig, E., et al. (1994) Expression of the apoptosis-related oncogenes bcl-2, bax, and p53 in Merkel cell carcinoma: can they predict treatment response and clinical outcome? Hum. Pathol. 30, 1367–1372.CrossRefGoogle Scholar
  31. 31.
    Broaddus, W. C., Liu, Y., Steele, L. L., et al. (1999) Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction. J. Neurosurg. 91, 997–1004.PubMedCrossRefGoogle Scholar
  32. 32.
    Sakakura, C., Sweeney, E. A., Shirahama, T., et al. (1996) Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int. J. Cancer 67, 101–105.PubMedCrossRefGoogle Scholar
  33. 33.
    Swisher, S., Roth, J. A., Komaki, R., et al. (2000) A phase II trial of adenoviral mediated p53 gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC). Am. Soc. Clin. Oncol. 19, 461a (abstr.).Google Scholar
  34. 34.
    Le Chevalier, T., Arriagada, R., Quoix, E., et al. (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J. Natl. Cancer Inst. 83, 417–423.PubMedCrossRefGoogle Scholar
  35. 35.
    Shimizu, N., Chen, J., Gamou, S., and Takayanagi, A. (1996) Immunogene approach toward cancer therapy using epidermal growth factor receptor-mediated gene delivery. Cancer Gene Ther. 3, 113–120.PubMedGoogle Scholar
  36. 36.
    Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., and Mendelsohn, J. (1983) Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl. Acad. Sci. USA 80, 1337–1341.PubMedCrossRefGoogle Scholar
  37. 37.
    Lukas, J., Parry, D., Aagaard, L., et al. (1995) Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375, 503–506.PubMedCrossRefGoogle Scholar
  38. 38.
    Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., et al. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669–672.PubMedCrossRefGoogle Scholar
  39. 39.
    Nature Editor (2000) Gene therapy—a loss of innocence. Nature6, 1.CrossRefGoogle Scholar
  40. 40.
    NIH (2001) Common toxicity criteria. NIH Website, http://ctep.info.nih.gov/ctc3/default.htm.
  41. 41.
    NIH/RAC (2001) Report of the Recombinant DNA Advisory Committee. NIH/OBA/RAC website, 3-8-2001, 6-27-2001, http://www4.od.nih.gov/oba/rac/minutes/march32001.pdf
  42. 42.
    NIH (2000) Report of The Working Group on Oversight of Clinical Gene Transfer Research. NIH, 7-12-2000.Google Scholar
  43. 43.
    Gibbs, W. W. (1996) Gene therapy. Scientific American website, http://www.sciam.com/explo-rations/101496explorations.html.
  44. 44.
    Wall Street Journal (1999) Gene therapy, touted as a breakthrough, bogs down in details. Wall Street Journal, October 27.Google Scholar
  45. 45.
    Anderson, W. F. (2001) A cure that may cost us ourselves. Newsweek, January 1.Google Scholar
  46. 46.
    NIH/RAC (2001) Reporting of adverse events in trials format. NIH, 6-1-2001, 7-27-2001, http://www4.od.nih.gov/oba/rac/SAEForm.rtf.
  47. 47.
    NIH/RAC (2001) NIH guidelines for research involving recombinant DNA molecules: RAC guidelines (revised Jan. 2001). NIH/RAC, http://www4.od.nih.gov/oba/rac/guidelines/guidejan01.htm.
  48. 48.
    NIH/OBA/RAC (2001) About Recombinant DNA Advisory Committee. NIH/OBA/RAC website, 7-27-2001, http://www4.od.nih.gov/oba/rac/aboutrdagt.htm.
  49. 49.
    NIH/OBA/RAC. (2001) Report of serious adverse effects. NIH/OBA/RAC website, 6-1-2001, 7-27-2001, http://www4.od.nih.gov/oba/rac/SAE_rpts/Mod0601s/Jun01_MODs.htm.
  50. 50.
    NCI (2001) NCI Cancer Trials website, 6-1-2001, 6-27-2001, http://cancertrials.nci.nih.gov/researchers/index.html.
  51. 51.
    Patterson, A. (2000) Statement of Amy Patterson, MD, Director, NIH Office for Biotecholgy Activities, Before The Subcommittee on Public Health, Committee on Heath, Education, Labor and Pensions, U.S. Senate, Feb. 2, 2000. NIH/OBA/RAC website, 7-25-2001, http://www4.od.nih.gov/aba/rac/patterson2-00.pdf.
  52. 52.
    NCI (2000) Restructuring clinical trials. NIH/NCI, 7-28-2001, http://cancertrials.nci.nih.gov/researchers/restructuring/blueprint/intro.html.
  53. 53.
    NIH/OBA/RAC (2001) NIH Guidelines Appendix M: points to consider in the design and submission of protocols for the transfer of recombinant DNA molecules into one or more uman research participants. NIH/OBA/RAC website, 1-1-2001, 7-27-2001, http://www4.od.nih.gov/oba/rac/guidelines/appendix_m.htm.
  54. 54.
    Zoon, K.C. (1999) Letter to IND Sponsors and Prinicipal Investigators. RAC, http://www4.od.nih.gov/oba/rac/genetherapyltr.pdf.
  55. 55.
    FDA (2001) Investigational New Drug (IND) Application. FDA/CDER website, 1-1-2001. http://www.fda.gov/cder/regulatory/applications/ind_page_1.htm.
  56. 56.
    FDA (2001) Handbook for Investigators—IND. FDA/CDER website, 1-1-2001, http://www.fda.gov/cder/handbook/ind.htm.
  57. 57.
    FDA (2001) Guidance for institutional review boards and clinical investigators. FDA, 1-1-2001, http://www.fda.gov/oc/ohrt/irbs/default.htm.
  58. 58.
    FDA (2001) FDA’s Health Professionals Page. FDA, 8-2-2001, 8-4-2001, http://www.fda.gov/oc/oha/default.htm.
  59. 59.
    NCI and NIH (2001) NCI clinical trials: a blueprint for the future. NCI-CancerTrials Website, 8-5-2001, http://cancertrials.nci.nih.gov/researchers/restructuring/blueprint/index.html.

Copyright information

© Humana Press Inc. 2003

Authors and Affiliations

  • Jack A. Roth
    • 1
  • Susan F. Grammer
    • 2
  1. 1.Department of Thoracic and Cardiovascular SurgeryUniversity of Texas M. D. Anderson Cancer CenterHouston
  2. 2.Biotechwrite: Biomedical and Science CommunicationsKalamazoo

Personalised recommendations